Translational Biomarker Core

翻译生物标志物核心（TBC）摘要 TBC是环境卓越中心暴露生物学计划的关键组成部分， 战略愿景中描述的毒理学（CEET）。核心测量暴露和效应的生物标志物， 疾病的发作和进展，以及对环境病因疾病的治疗反应。友爱会 采用严格的基于质谱（MS）的方法来鉴定基于细胞培养的生物标志物 在动物模型和人群和患者队列中，可以在整合模型中识别 健康科学设施核心。测量的分析物是小生物分子、蛋白质以及目标和 非靶向代谢组作为“代谢组”的报告者。友爱会认识到， 生物标志物的表型变化与转录组的变化或遗传变异有关， 通过CEET Informatics Core执行的数据集成实现。基因组、蛋白质组 代谢组学生物标志物有望提供新的诊断和预后指标， 可用于PRECISE环境医学（PREEM）在个人的基础上。TBC配备有 最先进的液相色谱-MS、超高效液相色谱（UPLC）-MS和UPLC- 高分辨率MS仪器。许多分析使用稳定同位素稀释LC-MS作为金标准， 精确度和准确度，并且许多测定不能在世界其他地方进行。的目标 核心是（i）分析来自模型系统的生物流体和生物流体中的暴露和影响的生物标志物， 人口队列和患者;（ii）提供发现和靶向蛋白质组学服务， 代谢组学;（iii）为CEET研究人员开发新的检测方法，并将这些检测方法转化为常规的核心 为其他CEET调查人员提供服务;以及（iv）为希望自己进行调查的最终用户提供培训。 分析.

Translational Biomarker Core (TBC) Abstract The TBC is a key component of the exposure biology program of the Center of Excellence in Environmental Toxicology (CEET) described in the Strategic Vision. The Core measures biomarkers of exposure and effect, disease onset and progression, and therapeutic response for diseases of environmental etiology. The TBC employs rigorous mass spectrometry (MS)-based methodology to identify biomarkers in cell-culture based models, in animal models and in population and patient cohorts that may be identified in the Integrative Health Sciences Facility Core. Analytes measured are small biomolecules, proteins, as well as targeted and untargeted metabolomes as reporters of the "exposome". The TBC recognizes that the need to relate phenotypic changes in biomarkers with either changes in the transcriptome or with genetic variants and this is achieved by data integration performed by the CEET Informatics Core. The integration of genomic, proteomic and metabolomics biomarkers offers the promise to deliver new diagnostic and prognostic indicators that can be used for PREcision Environmental Medicine (PREEM) on an individual basis. The TBC is equipped with state-of-the art liquid chromatography-MS, ultraperformance liquid chromatography (UPLC)-MS and UPLC- high resolution MS instrumentation. Many assays use stable-isotope dilution LC-MS as the gold standard for precision and accuracy and many of the assays cannot be performed elsewhere in the world. The goals of the Core are to (i) analyze biomarkers of exposure and effect in biofluids from model systems and in biofluids in population cohorts and patients; (ii) to provide services in discovery and targeted proteomics and metabolomics; (iii) to develop new assays for CEET investigators and translate these assays into routine Core services for other CEET investigators; and (iv) to provide training to end-users who wish to conduct their own analysis.